Insulet (MEX:PODD) Short-Term Debt: MXN335 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PODD Insulet Corp MEX:PODD
75 GF Score
Price MXN2,780.00
GF Value MXN8,219.87
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Short-Term Debt?

Insulet MEX:PODD 75 Short-Term Debt is MXN335 Mil as of Mar. 2026. GuruFocus rates MEX:PODD with a GF Score™ of 75/100 and a GF Value™ of MXN8,219.87 (Significantly Undervalued).

Insulet's Short-Term Debt for the quarter that ended in Mar. 2026 was MXN335 Mil.

Insulet's quarterly Short-Term Debt declined from Sep. 2025 (MXN1,466 Mil) to Dec. 2025 (MXN331 Mil) but then increased from Dec. 2025 (MXN331 Mil) to Mar. 2026 (MXN335 Mil).

Insulet's annual Short-Term Debt increased from Dec. 2023 (MXN839 Mil) to Dec. 2024 (MXN1,748 Mil) but then declined from Dec. 2024 (MXN1,748 Mil) to Dec. 2025 (MXN331 Mil).

Insulet Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Insulet Short-Term Debt Related Terms

Insulet Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Insulet's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Short-Term Debt Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 514.90 536.14 838.53 1,747.71 331.31

Insulet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,700.08 8,674.61 1,465.70 331.31 335.41
MEX:PODD
75GF Score
Insulet Corp MEX:PODD
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of MXN335 Mil mean?
Insulet (MEX:PODD) has a Short-Term Debt of MXN335 Mil as of Mar. 2026.
Is Insulet's Short-Term Debt too high?
Insulet's current Short-Term Debt is MXN335 Mil. Overall, Insulet has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Short-Term Debt compare to GMED and PEN?
Insulet's Short-Term Debt of MXN335 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Insulet's current Short-Term Debt is MXN335 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN8,219.87, compared to a current price of MXN2,780.00 — trading 66.2% below its estimated fair value. The current Short-Term Debt is MXN335 Mil. Insulet's overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Insulet (MEX:PODD), the current Short-Term Debt is MXN335 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MEX:PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of MXN2,780.00 is trading 66.2% below its estimated GF Value™ of MXN8,219.87. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for MEX:PODD:

  • Short-Term Debt: MXN335 Mil
  • GF Value™: MXN8,219.87 vs. price of MXN2,780.00 (66.2% below fair value)
  • GF Score™: 75/100

No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
75GF Score

Get the complete analysis for MEX:PODD

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,780.00
Price
MXN8,219.87
GF Value